Cargando…
Rational Design of a Novel Tubulin Inhibitor with a Unique Mechanism of Action
In this study, we capitalized on our previously performed crystallographic fragment screen and developed the antitubulin small molecule Todalam with only two rounds of straightforward chemical synthesis. Todalam binds to a novel tubulin site, disrupts microtubule networks in cells, arrests cells in...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324959/ https://www.ncbi.nlm.nih.gov/pubmed/35404502 http://dx.doi.org/10.1002/anie.202204052 |
_version_ | 1784756930782167040 |
---|---|
author | Mühlethaler, Tobias Milanos, Lampros Ortega, Jose Antonio Blum, Thorsten B. Gioia, Dario Roy, Bibhas Prota, Andrea E. Cavalli, Andrea Steinmetz, Michel O. |
author_facet | Mühlethaler, Tobias Milanos, Lampros Ortega, Jose Antonio Blum, Thorsten B. Gioia, Dario Roy, Bibhas Prota, Andrea E. Cavalli, Andrea Steinmetz, Michel O. |
author_sort | Mühlethaler, Tobias |
collection | PubMed |
description | In this study, we capitalized on our previously performed crystallographic fragment screen and developed the antitubulin small molecule Todalam with only two rounds of straightforward chemical synthesis. Todalam binds to a novel tubulin site, disrupts microtubule networks in cells, arrests cells in G2/M, induces cell death, and synergizes with vinblastine. The compound destabilizes microtubules by acting as a molecular plug that sterically inhibits the curved‐to‐straight conformational switch in the α‐tubulin subunit, and by sequestering tubulin dimers into assembly incompetent oligomers. Our results describe for the first time the generation of a fully rationally designed small molecule tubulin inhibitor from a fragment, which displays a unique molecular mechanism of action. They thus demonstrate the usefulness of tubulin‐binding fragments as valuable starting points for innovative antitubulin drug and chemical probe discovery campaigns. |
format | Online Article Text |
id | pubmed-9324959 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93249592022-07-30 Rational Design of a Novel Tubulin Inhibitor with a Unique Mechanism of Action Mühlethaler, Tobias Milanos, Lampros Ortega, Jose Antonio Blum, Thorsten B. Gioia, Dario Roy, Bibhas Prota, Andrea E. Cavalli, Andrea Steinmetz, Michel O. Angew Chem Int Ed Engl Research Articles In this study, we capitalized on our previously performed crystallographic fragment screen and developed the antitubulin small molecule Todalam with only two rounds of straightforward chemical synthesis. Todalam binds to a novel tubulin site, disrupts microtubule networks in cells, arrests cells in G2/M, induces cell death, and synergizes with vinblastine. The compound destabilizes microtubules by acting as a molecular plug that sterically inhibits the curved‐to‐straight conformational switch in the α‐tubulin subunit, and by sequestering tubulin dimers into assembly incompetent oligomers. Our results describe for the first time the generation of a fully rationally designed small molecule tubulin inhibitor from a fragment, which displays a unique molecular mechanism of action. They thus demonstrate the usefulness of tubulin‐binding fragments as valuable starting points for innovative antitubulin drug and chemical probe discovery campaigns. John Wiley and Sons Inc. 2022-04-25 2022-06-20 /pmc/articles/PMC9324959/ /pubmed/35404502 http://dx.doi.org/10.1002/anie.202204052 Text en © 2022 The Authors. Angewandte Chemie International Edition published by Wiley-VCH GmbH https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Research Articles Mühlethaler, Tobias Milanos, Lampros Ortega, Jose Antonio Blum, Thorsten B. Gioia, Dario Roy, Bibhas Prota, Andrea E. Cavalli, Andrea Steinmetz, Michel O. Rational Design of a Novel Tubulin Inhibitor with a Unique Mechanism of Action |
title | Rational Design of a Novel Tubulin Inhibitor with a Unique Mechanism of Action |
title_full | Rational Design of a Novel Tubulin Inhibitor with a Unique Mechanism of Action |
title_fullStr | Rational Design of a Novel Tubulin Inhibitor with a Unique Mechanism of Action |
title_full_unstemmed | Rational Design of a Novel Tubulin Inhibitor with a Unique Mechanism of Action |
title_short | Rational Design of a Novel Tubulin Inhibitor with a Unique Mechanism of Action |
title_sort | rational design of a novel tubulin inhibitor with a unique mechanism of action |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324959/ https://www.ncbi.nlm.nih.gov/pubmed/35404502 http://dx.doi.org/10.1002/anie.202204052 |
work_keys_str_mv | AT muhlethalertobias rationaldesignofanoveltubulininhibitorwithauniquemechanismofaction AT milanoslampros rationaldesignofanoveltubulininhibitorwithauniquemechanismofaction AT ortegajoseantonio rationaldesignofanoveltubulininhibitorwithauniquemechanismofaction AT blumthorstenb rationaldesignofanoveltubulininhibitorwithauniquemechanismofaction AT gioiadario rationaldesignofanoveltubulininhibitorwithauniquemechanismofaction AT roybibhas rationaldesignofanoveltubulininhibitorwithauniquemechanismofaction AT protaandreae rationaldesignofanoveltubulininhibitorwithauniquemechanismofaction AT cavalliandrea rationaldesignofanoveltubulininhibitorwithauniquemechanismofaction AT steinmetzmichelo rationaldesignofanoveltubulininhibitorwithauniquemechanismofaction |